C03627: Retinal Vein CatheterNovelty:
A new medical device to allow for localized drug delivery to treat occlusions of retinal vascular tissue.
Value Proposition:
A retinal vascular occlusion is characterized by a fully or partially blocked retinal vessel that limits the flow of blood through the retinal tissue. Restricted blood flow can impair vision in a variety of ways and, with an increase of pressure, cause a hemorrhage. Despite these risks, and the condition’s prevalence in patients over 50, there are limited treatment options. Clot dissolving drugs, called thrombolytic agents, have been successful in treating occluded vascular networks in other regions of the body. However, the unique vascular structure of the eye causes centralized delivery thrombolytics to diffuse quickly and lose effect. Increasing dosage further increases the risk of hemorrhage or stroke. This technology provides local access to an occluded retinal vein to allow for direct, concentrated dosages to be applied and break up the occlusion. Other advantages include:
• Does not need to be held in place by hand or surgical tool
• Flexible structure makes it less sensitive to motion
• Can be placed in vessels with at diameter of at least 100µm
Technical Details:
Johns Hopkins researchers have developed a microcatheter system which provides a means to dissolve clots in the vascular tissue via injection. After being placed near the occlusion site, the catheter is able to hold its position throughout the duration of the bolus delivery. In order to protect the integrity of this small structure from surgical tools, various designs are provided to assure accurate placement of the catheter.
Looking for Partners:
To develop and commercialize the technology as a new device in the Vitreoretinal Surgery Market to treat retinal vascular occlusions.
Stage of Development:
Prototype
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
American Journal of Ophthalmology. November 2004; Vol 138, Issue 5: Pages 829–839.
